Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical School, Dallas, Texas.
Surg Obes Relat Dis. 2013 Sep-Oct;9(5):743-8. doi: 10.1016/j.soard.2011.11.011. Epub 2011 Dec 3.
Calcium supplementation is commonly recommended for patients after Roux-en-Y gastric bypass to avert bone loss. To test the hypothesis that effervescent (liquid) potassium-calcium-citrate (PCC) might be more bioavailable than a tablet formulation of calcium citrate (Citracal Petite), the present study compared a single dose response of the 2 compounds. The present study was conducted at the University of Texas Southwestern Medical School at Dallas.
A total of 15 patients who had undergone Roux-en-Y gastric bypass were included in a 2-phase, crossover, randomized study comparing the single-dose bioavailability of PCC versus Citracal Petite. After following a restricted diet for 1 week, the participants ingested either a single dose of 400 mg elemental calcium as PCC or Citracal Petite. Sequential serum and urine samples were collected for a 6-hour period after the dose and analyzed for calcium, parathyroid hormone, and acid-base parameters.
Compared with citracal petite, PCC significantly increased the serum calcium concentrations at 2, 3, and 4 hours after the oral load. The peak to baseline variation and increment in serum calcium (area under the curve) were significantly greater after PCC (P = .015 and P = .002, respectively). Concurrently, the baseline to nadir variation and decrement in serum parathyroid hormone (area over the curve) were significantly greater after PCC (P = .004 and P = .005, respectively). Moreover, compared with Citracal Petite, PCC caused a significantly greater increment in urinary citrate (P < .0001) and potassium (P = .0004) and a significantly lower increase in urinary ammonium (P = .045).
In patients who have undergone Roux-en-Y gastric bypass, PCC was superior to Citracal Petite in conferring bioavailable calcium and suppressing parathyroid hormone secretion. PCC also provided an alkali load.
钙补充剂常用于 Roux-en-Y 胃旁路术后患者，以防止骨质流失。为了验证泡腾（液体）钾钙柠檬酸（PCC）比柠檬酸钙（Citracal Petite）片剂更具生物利用度的假设，本研究比较了这两种化合物的单次剂量反应。本研究在达拉斯的德克萨斯大学西南医学分校进行。
共有 15 名接受 Roux-en-Y 胃旁路手术的患者参加了一项 2 期、交叉、随机研究，比较了 PCC 与 Citracal Petite 的单次剂量生物利用度。在遵循限制饮食 1 周后，参与者摄入 400mg 元素钙的 PCC 或 Citracal Petite 单剂量。在剂量后 6 小时内采集连续血清和尿液样本，并分析钙、甲状旁腺激素和酸碱参数。
与 Citracal Petite 相比，PCC 在口服负荷后 2、3 和 4 小时显著增加血清钙浓度。PCC 后血清钙的峰基变化和增量（曲线下面积）显著更大（P =.015 和 P =.002）。同时，PCC 后血清甲状旁腺激素的基峰变化和减少（曲线面积）显著更大（P =.004 和 P =.005）。此外，与 Citracal Petite 相比，PCC 导致尿柠檬酸盐（P <.0001）和钾（P =.0004）的增加显著更大，而尿铵（P =.045）的增加显著更小。
在接受 Roux-en-Y 胃旁路手术的患者中，PCC 在提供生物利用钙和抑制甲状旁腺激素分泌方面优于 Citracal Petite。PCC 还提供了碱负荷。
